# Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant

> **NCT02232178** · PHASE2 · COMPLETED · sponsor: **Innocoll** · enrollment: 64 (actual)

## Conditions studied

- Hernioplasty

## Interventions

- **DRUG:** 2 100mg Xaracoll implants
- **DRUG:** 3 100mg Xaracoll implants
- **DRUG:** 150mg Bupivacaine HCl injection

## Key facts

- **NCT ID:** NCT02232178
- **Lead sponsor:** Innocoll
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-20
- **Primary completion:** 2015-02-23
- **Final completion:** 2015-03-23
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2020-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02232178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02232178, "Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02232178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*